The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

M. V. Blagosklonny, T. Fojo, K. N. Bhalla, J. S. Kim, J. B. Trepel, W. D. Figg, Y. Rivera, L. M. Neckers

Research output: Contribution to journalArticlepeer-review

127 Scopus citations

Fingerprint

Dive into the research topics of 'The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences